Cancer Drug Targets Specific Cells

AUGUST 01, 2006
Susan Farley

GlaxoSmithKline's phase 2 clinical trial of the investigational drug MAGE-A3 Antigen Specific Cancer Immunotherapeutic (ASCI) for the treatment of non-small-cell lung cancer (NSCLC) showed a reduction in cancer recurrence following surgery, when compared with placebo. In the trial, all patients had tumors that expressed a tumor-specific antigen—MAGE-A3—seen in 35% to 50% of early NSCLC. The multicenter, randomized, double-blind, placebo-controlled trial included 182 patients receiving either MAGE-A3 ASCI or placebo. Relapse occurred in 30.3% of patients in the MAGE-A3 group, compared with 41.7% of patients in the placebo group. This new cancer immunotherapy resulted in a 33% reduction of risk. Phase 3 clinical trials are set for early 2007. Trial results were presented at the American Society of Clinical Oncology's annual meeting in Atlanta, Ga.

Ms. Farley is a freelance medical writer based in Wakefield, RI.




SHARE THIS SHARE THIS
0
 

CROI 2017: Daily Oral PrEP Effective Even in Presence of Bacterial Vaginosis

Women with abnormal vaginal microbiota showed no difference in efficacy of daily oral PrEP compared to women with normal vaginal microbiota.


 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.